iBio, Inc. (IBIO)
Stock Price:
$3.80 USD
-0.26 (-6.40%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
532.46M |
| Revenue (ttm) |
1.31M |
| Net Income (ttm) |
-17.40M |
| Shares Out |
143.88M |
| EPS (ttm) |
-0.98 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 7, 2020 |
| Last Price |
$3.80 |
| Previous Close |
$4.06 |
| Change ($) |
-0.26 |
| Change (%) |
-6.40% |
| Day's Open |
3.93 |
| Day's Range |
3.62 - 4.14 |
| Day's Volume |
17,369,814 |
| 52-Week Range |
0.05 - 7.45 |
More Stats
| Market Cap |
532.46M |
| Enterprise Value |
556.00M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
143.88M |
| Float |
109.49M |
| EPS (basic) |
-1.19 |
| EPS (diluted) |
-0.98 |
| FCF / Share |
-0.18 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
2.94M |
| Short Ratio |
0.12 |
| Short % of Float |
3.32% |
| Beta |
-5.45 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
405.53 |
| PB Ratio |
147.30 |
| Revenue |
1.31M |
| Operating Income |
-15.13M |
| Net Income |
-17.40M |
| Free Cash Flow |
-14.38M |
| Net Cash |
-23.54M |
| Net Cash / Share |
-0.17 |
| Gross Margin |
153.69% |
| Operating Margin |
-1,152.09% |
| Profit Margin |
-2,987.40% |
| FCF Margin |
-1,094.97% |
| ROA |
-23.99% |
| ROE |
-320.62% |
| ROIC |
-27.10% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
30.0
Current: $3.80
High
30.0
Target: 30.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 2.02 | 0.44 | 0.39 | 0.95 | 1.85 | 0.21 | 1.01 | 1.28 | 0.52 | - |
| Revenue Growth | 354.5% | 12.69% | -58.44% | -48.78% | 802.93% | -79.64% | -21.14% | 145.54% | - | - |
| Gross Profit | 2.02 | 0.44 | 0.39 | 0.95 | 1.85 | 0.21 | 1.01 | 1.28 | 0.52 | - |
| Operating Income | -15.79 | -14.23 | -14.27 | -9.89 | -6.67 | -3.84 | -6.67 | -9.33 | -9.65 | -4.59 |
| Net Income | -17.59 | -16.11 | -14.53 | -9.76 | -6.63 | -3.67 | -6.20 | -5.68 | -12.14 | -6.08 |
| Shares Outstanding | 18.93 | 10.63 | 8.91 | 8.10 | 7.15 | 6.30 | 4.94 | 3.95 | 3.10 | 2.73 |
| Earnings Per Share | -0.94 | -1.54 | -1.64 | -1.20 | -0.90 | -0.60 | -1.30 | -1.40 | -3.90 | -2.20 |
| Operating Cash Flow | -13.98 | -13.48 | -13.16 | -8.07 | -4.73 | -4.12 | -4.85 | -6.01 | -5.34 | -2.35 |
| Capital Expenditures | -0.99 | -1.08 | -1.59 | -0.07 | -0.22 | -0.26 | -0.20 | -0.25 | -0.09 | - |
| Free Cash Flow | -14.97 | -14.56 | -14.76 | -8.14 | -4.94 | -4.38 | -5.04 | -6.26 | -5.43 | -2.35 |
| Cash & Equivalents | 4.42 | 15.93 | 8.09 | 23.01 | 9.49 | 3.59 | 4.41 | 5.62 | 2.84 | 0.91 |
| Total Debt | 24.88 | 25.08 | 25.27 | 25.44 | - | - | - | - | - | - |
| Net Cash / Debt | -20.46 | -9.15 | -17.18 | -2.42 | 9.49 | 3.59 | 4.41 | 5.62 | 2.84 | 0.91 |
| Assets | 30.59 | 43.08 | 36.01 | 51.60 | 12.49 | 6.49 | 9.35 | 9.77 | 7.34 | 4.93 |
| Liabilities | 28.13 | 26.92 | 27.10 | 27.56 | 1.26 | 0.40 | 4.29 | 3.60 | 7.14 | 3.85 |
| Book Value | 2.46 | 16.17 | 8.91 | 9.94 | 11.23 | 6.10 | 5.07 | 6.17 | 0.20 | 1.08 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
iBio, Inc. |
| Country |
United States |
| Employees |
55 |
| CEO |
Thomas F. Isett |
Stock Information
| Ticker Symbol |
IBIO |
| Stock Exchange |
NYSE American |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NYSEAMERICAN: IBIO |
Description
iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The company's services cover the stages of pre-clinical development, regulatory approval, commercial product launch, and on-going commercial phase requirements. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. The company is also developing vaccine candidates for third parties. It has a license agreement with the University of Natural Resources and Life Sciences, Vienna; a strategic relationship with Beijing CC-Pharming Ltd.; and collaboration agreements with AzarGen Biotechnologies (Pty) Ltd, The Texas A&M University System, and Fraunhofer Center for Molecular Biotechnology. In addition, the company offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is headquartered in New York, New York.